CNTB — Connect Biopharma Holdings Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1835268 ·
Last close
$0.58
Market Cap
$36.45M
52W High
$3.82
52W Low
$0.55
ADV30
815,824
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 2,768,000 | — | -17,604,000 | -17,284,000 | 43,472,000 | 27,015,000 | 16,611,000 |
| Mar 2026 | 169,000 | — | -19,607,000 | -19,398,000 | 60,066,000 | 46,034,000 | 17,443,000 |
| Dec 2025 | 0 | — | -15,526,000 | -15,109,000 | 56,075,000 | 38,345,000 | 14,095,000 |
| Sep 2025 | 16,000 | — | -17,677,000 | -17,200,000 | 67,361,000 | 37,845,000 | 11,990,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,583,000
Investing CF
$26,861,000
Financing CF
$19,879,000
CapEx
$-434,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.19
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-437,517,000
Inventory
—
Receivables
$2,958,000
ST Investments
$4,471,000
EBIT TTM
$-70,414,000
Pretax Income TTM
$-68,795,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,953,000
EBITDA
$-69,729,000
Free Cash Flow
$-34,712,752
Enterprise Value
$97,577,592
Total Cash
$31,486,000
Total Debt
$596,000
Shares Out
62,974,309
Trailing EPS
$-1.19
Book Value
$0.43
ROE
-140.5%
ROA
-69.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 64,000 | -58,074,000 | -55,480,000 | 56,075,000 | 14,095,000 | 41,980,000 | -51,206,000 |
| Dec 2024 | 26,033,000 | -22,452,000 | -15,628,000 | 101,284,000 | 9,118,000 | 92,166,000 | -23,612,000 |
| Dec 2023 | 0 | -69,056,000 | -62,106,000 | 127,375,000 | 25,878,000 | 101,497,000 | -47,741,000 |
| Dec 2022 | 0 | -116,507,000 | -118,091,000 | 174,013,000 | 16,521,000 | 157,492,000 | -101,520,000 |
TTM Snapshot
Revenues TTM
$2,953,000
NetIncome TTM
$-68,991,000
OpCashFlow TTM
—
Assets (Latest)
$43,472,000
Forward EPS
$-0.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VERU | VERU INC. | $36.49M | $2.14 | — |
| SER | Serina Therapeutics, Inc. | $36.27M | $1.37 | — |
| GRCE | Grace Therapeutics, Inc. | $36.18M | $1.72 | — |
| BMEA | Biomea Fusion, Inc. | $35.47M | $0.49 | — |
| OSTX | OS Therapies Inc | $34.86M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
Connect Biopharma Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 21:05 · Yahoo
Connect Biopharma Holdings (CNTB) Stock Sees Modest Fair Value Lift After Trial Driven Revisions
2026-11-11 04:35 · Yahoo
Down 25.4% in 4 Weeks, Here's Why Connect Biopharma Holdings (CNTB) Looks Ripe for a Turnaround
2026-10-22 12:35 · Yahoo
Here's Why Connect Biopharma Holdings (CNTB) Could be Great Choice for a Bottom Fisher
2026-10-19 12:55 · Yahoo
Connect Biopharma COPD Study Shows 81% Cut in Treatment Failures
2026-10-04 07:02 · Yahoo
Connect Biopharma Reports Positive Phase 2 Rademikibart COPD Data, Plans FDA Talks on Phase 3 Program
2026-09-30 14:43 · Yahoo
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
2026-09-30 11:00 · Yahoo
Connect Biopharma (CNTB) Misses Key Asthma Trial Goal. Can its Drug Still Move Forward?
2026-09-22 23:45 · Yahoo
Connect Biopharma Rademikibart Phase 2 Data Shows Lung Function Improvement but Primary Endpoint Misses Significance
2026-09-15 15:01 · Yahoo
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-03 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.